Patient and Caregiver Preferences for Long‐Term Prophylactic Treatment of Bleeds in Haemophilia: A Discrete‐Choice Experiment
Participants highly value avoiding daily administration and reducing bleeds, and they are willing to accept increased risks or reduced efficacy to have subcutaneous rather than intravenous administration. As new treatments become available, understanding these preferences can facilitate shared decision-making in treatment selection and enhance patient-centred drug development and patient communication.
Authors
- Stephanie Christopher (ORCID: https://orcid.org/0000-0001-5792-8393)
- Brett Hauber (ORCID: https://orcid.org/0000-0003-3129-7268)
- Alexis Sohn (ORCID: https://orcid.org/0009-0007-3207-760X)
- A. Carmine Colavecchia (ORCID: https://orcid.org/0000-0003-4937-0654)
- Joshua Coulter (ORCID: https://orcid.org/0000-0002-1795-8536)
- Travis J. Gould (ORCID: https://orcid.org/0009-0007-9416-1890)
- Pratima Chowdary (ORCID: https://orcid.org/0000-0002-6690-8586)
- Lisa J. Wilcox (ORCID: https://orcid.org/0009-0001-2642-4827)
- Joseph C. Cappelleri (ORCID: https://orcid.org/0000-0001-9586-0748)
- Hui Juan Lu (ORCID: https://orcid.org/0000-0001-8347-0830)
- Jennifer A. Whitty (ORCID: https://orcid.org/0000-0002-5886-1933)
- Nicola Dunn
- Álvaro A Gutiérrez-Vargas
Institutions
- Pfizer (United States) (US)
- The Royal Free Hospital (GB)
- Thermo Fisher Scientific (United Kingdom) (GB)
- University College London (GB)
Publication Details
- Journal
- Haemophilia
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1111/hae.70172
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00